AdvtBy ,ET BureauJoin the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. Download the ETPharma App and get the Realtime updates and Save your favourite articles. "Any diversion, leakage into unauthorised channels, promotions influencing supply practices, or non-adherence to approval conditions should be viewed seriously with appropriate regulatory action," the letter said. All State and Union Territory drug controllers have also been asked to actively monitor print, electronic, digital, social-media, and outdoor platforms for non-compliant advertisements or surrogate promotional activities relating to these drugs.

Source: Economic Times March 28, 2026 10:32 UTC